Biocon is retaining economic interest in global commercialization of Hulio, (biosimilar Adalimumab) in-licensed by Mylan.
Following the successful approval and European launch of Hulio, (biosimilar Adalimumab) in-licensed by the company’s partner Mylan from Fujifilm Kyowa Kirin Biologics, the commercialization rights have been extended from Europe to Global Markets. Biocon, under the terms of its global partnership with Mylan for monoclonal antibodies, retains its economic interest in this expanded in-licensing arrangement and will gain a share of profits from Global Markets. Biocon is committed to enable patient access to affordable biosimilars and this partnership accelerates that process.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient’s worldwide.
The post Biocon retains economic interest in global commercialization of Hulio in-licensed by Mylan appeared first on Udaipur News | Udaipur Latest News | udaipur local news.
